Compare FBP & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBP | ICUI |
|---|---|---|
| Founded | 1948 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2010 | 1995 |
| Metric | FBP | ICUI |
|---|---|---|
| Price | $26.23 | $148.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $25.50 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.7M | 261.1K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | 18.78 | ★ 100.62 |
| EPS | 0.57 | ★ 1.20 |
| Revenue | $1,255,034,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.65 | $4.46 |
| P/E Ratio | ★ $46.56 | $123.97 |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $19.16 | $107.02 |
| 52 Week High | $26.80 | $160.29 |
| Indicator | FBP | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 66.08 | 65.05 |
| Support Level | $23.30 | $146.59 |
| Resistance Level | N/A | $153.00 |
| Average True Range (ATR) | 0.48 | 4.63 |
| MACD | 0.12 | 0.42 |
| Stochastic Oscillator | 73.19 | 79.92 |
First BanCorp is a financial holding company. The company's operating segment includes Mortgage Banking; Consumer (Retail) Banking; Commercial and Corporate Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. The Consumer (Retail) Banking segment generates the majority of revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.